SCHEMBL21467052

SCHEMBL21467052

CCc1n[nH]c2cc(-c3n[nH]c4ncnc(N)c34)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.48
PIK3CD O00329 2/20 0.48
ABL1 P00519 2/20 0.48
EGFR P00533 2/20 0.48
HCK P08631 2/20 0.48
SRC P12931 2/20 0.48
PIK3CA P42336 2/20 0.48
PIK3CB P42338 2/20 0.48
MTOR P42345 2/20 0.48
PIK3CG P48736 2/20 0.48
EPHB4 P54760 2/20 0.48
PRKDC P78527 2/20 0.48
PDPK1 O15530 11/20 0.41
FGFR1 P11362 2/20 0.40
AURKA O14965 4/20 0.39
TGFBR1 P36897 4/20 0.39
AURKB Q96GD4 4/20 0.39
FGFR2 P21802 2/20 0.39
FGFR3 P22607 1/20 0.39
SGK1 O00141 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17970655 0.84 KDR (0.51) KDRPIK3CDABL1EGFRHCK
SCHEMBL129826 0.81 PIK3CD (0.60) KDRPIK3CDABL1EGFRHCK
SCHEMBL17970622 0.77 KDR (0.44) KDRPIK3CDABL1EGFRHCK
SCHEMBL21467105 0.77 JAK2 (0.46) KDRPIK3CDABL1EGFRHCK
SCHEMBL21467047 0.75 FGFR1 (0.45) KDRPIK3CDABL1EGFRHCK
SCHEMBL13717511 0.74 PIK3CD (0.37) KDRPIK3CDABL1EGFRHCK
SCHEMBL23917483 0.73 PIK3CD (0.60) KDRPIK3CDABL1EGFRHCK
SCHEMBL21467059 0.73 ABL1 (0.58) KDRPIK3CDABL1EGFRHCK
SCHEMBL31367061 0.73 ABL1 (0.58) KDRPIK3CDABL1EGFRHCK
SCHEMBL21467079 0.72 TGFBR1 (0.46) KDRPIK3CDABL1EGFRHCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 KDR 866/4885PIK3CD 2/4885ABL1 329/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A KDR 823/4885PIK3CD 103/4885ABL1 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.